このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Bridge Biotherapeutics マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

James Jungkue Lee

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	9.2%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

Here's Why We're Not Too Worried About Bridge Biotherapeutics' (KOSDAQ:288330) Cash Burn Situation

Feb 17

A Look At Bridge Biotherapeutics' (KOSDAQ:288330) Share Price Returns

Dec 23

CEO（最高経営責任者

James Jungkue Lee

no data

在職期間

Mr. James Jungkue Lee serves as Chief Executive Officer and Director at Bridge Biotherapeutics Inc. Mr. Lee founded Bridge Biotherapeutics, Inc. in 2015. Mr. James Jungkue Lee served as the Vice President...

Bridge Biotherapeutics マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Bridge Biotherapeutics, Inc., Annual General Meeting, Mar 26, 2024

Insufficient new directors

Insufficient new directors

Bridge Biotherapeutics, Inc., Annual General Meeting, Mar 30, 2021

Recent updates

New major risk - Shareholder dilution

Bridge Biotherapeutics Announces Completion of Enrollment in the Phase 2a Clinical Study of BBT-877 for the Treatment of Idiopathic Pulmonary Fibrosis

Bridge Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of KRW 21.5364 billion.

New major risk - Share price stability

Full year 2023 earnings released: ₩2,059 loss per share (vs ₩2,102 loss in FY 2022)

New major risk - Revenue size

Bridge Biotherapeutics, Inc., Annual General Meeting, Mar 26, 2024

Bridge Biotherapeutics, Inc. announced that it has received KRW 1.99999872 billion in funding

Third quarter 2023 earnings released: ₩387 loss per share (vs ₩540 loss in 3Q 2022)

Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC

Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis

New minor risk - Shareholder dilution

Bridge Biotherapeutics, Inc. announced that it has received KRW 5.9999904 billion in funding

New minor risk - Share price stability

New minor risk - Market cap size

Insufficient new directors

Bridge Biotherapeutics, Inc. Initiates Phase 2 Clinical Trial of BBT-877 in Patients with Idiopathic Pulmonary Fibrosis

Bridge Biotherapeutics, Inc. Presents Non-Clinical Study Results for 2 IPF Candidates at the IPF Summit 2022

Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877

Bridge Biotherapeutics Presents Promising Interim Clinical Study Results from Phase 1 Study of BBT-176 at WCLC 2022

Insufficient new directors

Bridge Biotherapeutics, Inc. Presents Preclinical Data of BBT-207 at the AACR Annual Meeting 2022

Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis

Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for Bbt-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site

Bridge Biotherapeutics, Inc., Annual General Meeting, Mar 30, 2021

Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 4.999995 billion in funding from LegoChem Biosciences, Inc.

New 90-day high: ₩16,700

Here's Why We're Not Too Worried About Bridge Biotherapeutics' (KOSDAQ:288330) Cash Burn Situation

New 90-day high: ₩15,800

A Look At Bridge Biotherapeutics' (KOSDAQ:288330) Share Price Returns

Bridge Biotherapeutics, Inc. Announces Termination of Collaboration and License Agreement with Boehringer Ingelheim

Bridge Biotherapeutics Announces Detailed Plans for the Phase 2A Study of BBT-401

New 90-day high - ₩47,300

New 90-day low - ₩37,950

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04